Grace Therapeutics, Inc. (GRCE) — Cash Flow-to-Debt Ratio
Grace Therapeutics, Inc. (GRCE) has a Cash Flow-to-Debt Ratio of -0.62x as of December 2025, meaning its operating cash flow of $-2.22 Million could theoretically repay -1% of its total liabilities ($3.60 Million) in one year. See GRCE cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Grace Therapeutics, Inc. Cash Flow-to-Debt Ratio (2010–2025)
Historical debt coverage capacity for Grace Therapeutics, Inc. across 15 annual periods. Also explore GRCE net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Grace Therapeutics, Inc. (2010–2025)
Year-by-year debt coverage analysis for Grace Therapeutics, Inc.. For market capitalisation and broader financial context, see Grace Therapeutics, Inc. (GRCE) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.77x | $-14.90 Million | $5.38 Million | ▼ -159.5% |
| 2024 | -1.07x | $-12.33 Million | $11.56 Million | ▲ +25.1% |
| 2023 | -1.42x | $-15.91 Million | $11.17 Million | ▼ -68.2% |
| 2022 | -0.85x | $-17.23 Million | $20.35 Million | ▲ +59.8% |
| 2021 | -2.11x | $-14.32 Million | $6.80 Million | ▲ +9.5% |
| 2020 | -2.33x | $-22.95 Million | $9.86 Million | ▼ -142.8% |
| 2019 | -0.96x | $-24.79 Million | $25.85 Million | ▼ -12.9% |
| 2018 | -0.85x | $-9.69 Million | $11.41 Million | ▲ +83.2% |
| 2016 | -5.07x | $-4.85 Million | $957.12K | ▼ -180.2% |
| 2015 | -1.81x | $-5.75 Million | $3.18 Million | ▼ -228.3% |
| 2014 | -0.55x | $-6.12 Million | $11.10 Million | ▲ +47.1% |
| 2013 | -1.04x | $-2.49 Million | $2.39 Million | ▲ +76.6% |
| 2012 | -4.46x | $-5.65 Million | $1.27 Million | ▼ -1120.5% |
| 2011 | -0.37x | $-1.91 Million | $5.24 Million | ▲ +6.2% |
| 2010 | -0.39x | $-1.90 Million | $4.88 Million | — |